Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Targeting AML through DR4 with a novel variant of rhTRAIL

Szegezdi, Eva, Reis, Carlos R., Sloot, Almer M. van der, Natoni, Alessandro, O'Reilly, Aoife, Reeve, Janice, Cool, Robbert H., O'Dwyer, Michael, Knapper, Steven, Serrano, Luis, Quax, Wim J. and Samali, Afshin 2011. Targeting AML through DR4 with a novel variant of rhTRAIL. Journal of Cellular and Molecular Medicine 15 (10) , pp. 2216-2231. 10.1111/j.1582-4934.2010.01211.x

[img]
Preview
PDF - Published Version
Download (1MB) | Preview

Abstract

Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different types of tumours, but AML cells are relatively insensitive to TRAIL-induced apoptosis. Here we show that TRAIL-induced apoptosis in AML cells is predominantly mediated by death receptor 4 (DR4) and not DR5. Therefore, we constructed a variant of TRAIL (rhTRAIL-C3) that is a strong inducer of DR4-mediated apoptosis. TRAIL-C3 demonstrated much stronger pro-apoptotic activity than wild-type (WT) TRAIL in a panel of AML cell lines as well as in primary AML blasts. The higher pro-apoptotic potential was further enhanced when the TRAIL mutant was used in combination with BMS-345541, a selective inhibitor of inhibitor-κB kinases. It illustrates that combination of this TRAIL variant with chemotherapeutics or other targeted agents can kill AML with high efficacy. This may represent a major advantage over the currently used therapies that have serious toxic side effects. The high efficacy of rhTRAIL-C3 containing therapies may enable the use of lower drug doses to reduce the toxic side effects and improve patient outcome. Our findings suggest that the rational design of TRAIL variants that target DR4 potentiate the death-inducing activity of TRAIL and offer a novel therapeutic strategy for the treatment of AML.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: apoptosis; death receptor 4 (DR4); DR5; tumour necrosis factor-related apoptosis-inducing ligand (TRAIL); acute myelogenous leukaemia (AML); receptor-selective TRAIL variant; primary AML blast
Additional Information: Pdf uploaded in accordance with publisher's policy at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934/homepage/open_access_license_and_copyright.htm (accessed 24/04/2014).
Publisher: Carol Davila University Press
ISSN: 1582-1838
Date of First Compliant Deposit: 30 March 2016
Last Modified: 04 Jun 2017 03:50
URI: http://orca.cf.ac.uk/id/eprint/27597

Citation Data

Cited 21 times in Google Scholar. View in Google Scholar

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics